Artificial Intelligence-enabled Chest Scan Improves Pulmonary Hypertension Diagnosis

A new artificial intelligence-enabled chest imaging technology performs a deep characterization of the pulmonary vasculature to detect pulmonary (arterial) hypertension.

The new feature of Thirona’s AI-based lung quantification platform LungQ™ allows more objective and sensitive quantification of vascular abnormalities from non-contrast CT, with high precision. This in turn helps to detect pulmonary (arterial) hypertension.

It separately identifies the arteries and veins from the scan and accurately quantifies vessel diameters and volumes down to the sub-voxel range, which is crucial to obtain a sensitive and precise analysis.

Pulmonary Hypertension
Hypertension or high blood pressure as is generally a well known condition, however no one is aware of another type of hypertension called â€˜Pulmonary Hypertensionâ€™ â€“ a rare condition that affects the lungs.

‘A global company specialized in advanced analysis of thoracic CT images announces its new artificial intelligence (AI) -based algorithm for pulmonary hypertension diagnosis, LungQ™ AVX.# Pulmonary Hypertension #machine learning #pulmonary vein’

Primary studies, presented the past week at the ATS 2023 International Conference in Washington, show that AVX allows for non-invasive detection of arterial and venous alterations in the lungs, potentially enabling early diagnosis of P(A)H and differentiating between different vascular disease types such as PH groups (WHO classification).
Novel Artificial Intelligence Framework to Detect Pulmonary Hypertension Precisely The practical implications of the potential of LungQ™ include diagnostic support (), robust measurements of treatment outcomes, and more accurate medical and pharmaceutical research.

LungQ™ AVX does not require a contrast-enhanced CT, its sensitivity and accuracy allow for deep quantification of the pulmonary vasculature in routine CT scans without the need for invasive procedures for the patients.

The insights provided by LungQ™ AVX cannot be subjectively assessed from a CT scan as the eye is not sensitive enough to pick up subtle changes in the dimensions of the pulmonary arteries and veins.

Probiotics may Emerge as Novel Drug Delivery Systems in Pulmonary Hypertension
Researchers have found that genetically modified probiotic bacterium lactobacillus may be used to deliver Angiotensin-(1-7) in pulmonary hypertension.

AVX could potentially help PH diagnosis by detecting relevant vascular alterations way earlier than they can be picked up by the current golden standard of hemodynamic measurements by right-heart catheterization.

The expectation is that AV phenotyping will have the most noteworthy benefits in detecting pulmonary hypertension (PH) and its subtypes. PH is a rare disease with a very high underdiagnosis rate.

Hormone Adjustment may Prevent and Treat Lung Damage in Premature Infants
Hormone adrenomedullin plays an important role in the development, recovery, and prevention of bronchopulmonary dysplasia (BPD) and pulmonary hypertension (PH), reports a new study.

Applying AI to help with its early detection can potentially result in slowing the disease progression in PH patients by ensuring they get the best possible treatment sooner.

It is an exciting step forward in phenotyping pulmonary vascular disease (). AVX is a result of almost a decade of research and development work aimed at finding vascular phenotypes to improve the diagnosis of a multitude of vascular diseases and to identify new potential therapeutic targets.

New Approach to Enhance Pulmonary Hypertension Diagnosis Developed
New technical approach to enhance the diagnosis of pulmonary hypertension was discovered by scientists.

Today, we have several validation studies delivering strong evidence that AVX can potentially transform the way we diagnose and treat incurable diseases like pulmonary (arterial) hypertension. And more studies are pending.

References:

Artificial intelligence applied in pulmonary hypertension: a bibliometric analysis - (https://link.springer.com/article/10.1007/s43681-023-00267-8)
A transparent artificial intelligence framework to assess lung disease in pulmonary hypertension - (https://www.nature.com/articles/s41598-023-30503-4)

Source-Medindia